5 results match your criteria: "Bankstown and Concord Hospitals[Affiliation]"
Risk of Colorectal Neoplasia in Individuals With Self-Reported Family History: A Prospective Colonoscopy Study from 16 Asia-Pacific Regions.
Am J Gastroenterol
November 2016
CUHK JC Bowel Cancer Education Centre, Institute of Digestive Disease, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Objectives: We tested the hypothesis that the risk of colorectal cancer (CRC), advanced colorectal neoplasia (ACN), and colorectal adenoma among screening participants with different first-degree relatives (FDRs) affected by CRC was similar.
Methods: A multi-center, prospective colonoscopy study involving 16 Asia-Pacific regions was performed from 2008 to 2015. Consecutive self-referred CRC screening participants aged 40-70 years were recruited, and each subject received one direct optical colonoscopy.
A Risk-Scoring System Combined With a Fecal Immunochemical Test Is Effective in Screening High-Risk Subjects for Early Colonoscopy to Detect Advanced Colorectal Neoplasms.
Gastroenterology
March 2016
Institute of Digestive Disease, The Chinese University of Hong Kong, Shatin, New Territory, Hong Kong. Electronic address:
Background & Aims: Age, sex, smoking, and family history are risk factors for colorectal cancer in Asia. The Asia-Pacific Colorectal Screening (APCS) scoring system was developed to identify subjects with a high risk for advanced neoplasm (AN). We tested an algorithm that combined APCS scores with fecal immunochemical test (FIT) in colorectal cancer screening.
View Article and Find Full Text PDFEnvironmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific.
Gut
July 2015
Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Institute of Digestive Disease, Li Ka Shing Institute of Health Science, Hong Kong, China.
Objective: The rising incidence of inflammatory bowel disease in Asia supports the importance of environmental risk factors in disease aetiology. This prospective population-based case-control study in Asia-Pacific examined risk factors prior to patients developing IBD.
Design: 442 incident cases (186 Crohn's disease (CD); 256 UC; 374 Asians) diagnosed between 2011 and 2013 from eight countries in Asia and Australia and 940 controls (frequency-matched by sex, age and geographical location; 789 Asians) completed an environmental factor questionnaire at diagnosis.
Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study.
Gastroenterology
July 2013
Institute of Digestive Disease, Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
Article Synopsis
- The Asia-Pacific Crohn's and Colitis Epidemiology Study aimed to assess the incidence and characteristics of inflammatory bowel diseases (IBD) in 8 Asian countries and Australia, as IBD is increasing in prevalence in Asia.
- The study identified 419 new IBD cases within one year, with the incidence per 100,000 individuals being significantly lower in Asia (1.37) compared to Australia (23.67), but noted that China had the highest rate in Asia at 3.44.
- Findings showed that complicated Crohn's disease is more frequent in Asia compared to Australia, and that the emergence of IBD in Asia necessitates tailored healthcare resources and offers a chance to explore its causes.
Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.
Expert Opin Drug Saf
September 2008
The University of New South Wales, Bankstown and Concord Hospitals, Gastroenterology and Liver Services, Sydney South West Area Health Service, Sydney, Australia.
Background: Immunomodulator therapy with the thiopurine analogues azathioprine or 6-mercaptopurine is commonly prescribed for the treatment of inflammatory bowel disease (IBD). Drug adverse effects and the lack of efficacy, however, commonly require withdrawal of therapy. Allopurinol, a xanthine oxidase inhibitor, was recently evaluated in its role in modifying thiopurine metabolism and improving drug efficacy in IBD.
View Article and Find Full Text PDF